A TCOYD Sit Down with Breakthrough T1D/JDRF’s CEO Aaron Kowalski discussing recent research breakthroughs in type 1 diabetes, focusing on three main areas: improving lives through technology and medications, disease-modifying therapies to address the autoimmune nature of type 1 diabetes, and cellular replacement therapies. The conversation highlights advancements in hybrid closed-loop systems, emerging drugs for better glucose control, screening for early detection, and promising stem cell research that could lead to a cure. Kowalski expresses optimism about the future, suggesting that cell therapy products could be available within this decade, potentially allowing some people with type 1 diabetes to stop using insulin pumps.